Skip to main content

Advertisement

Table 2 Associations between CYP17 genetic polymorphisms and breast cancer by menopausal status: Western New York Breast Cancer Study

From: CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors

  Case (n [%]) Control (n [%]) Crude odds ratio (95% CI) Adjusted odds ratio (95% CI)a
Premenopausal (n = 182)
   A1/A1 58 (61) 48 (56) 1.00 1.00
   A1/A2 31 (32) 28 (33) 0.92(0.48–1.73) 0.85(0.44–1.63)
   A2/A2 7 (7) 10 (11) 0.58(0.21–1.64) 0.56(0.20–1.62)
Postmenopausal (n = 213)
   A1/A1 51 (46) 47 (46) 1.00 1.00
   A1/A2 52 (47) 43 (42) 1.10 (0.63–1.90) 0.97 (0.45–2.20)
   A2/A2 8 (7) 12 (12) 0.60 (0.23–1.60) 0.45 (0.13–1.60)
  1. a Adjusted for age, education, family history of breast cancer, body mass index, and history of benign breast disease (and age at menopause in postmenopausal women). CI, confidence interval.